Advancing Bispecific Biologic Therapies for Solid Tumors and Blood Cancers

No Comments

In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses how AbbVie is advancing the development of bispecific biologic therapies in both solid tumors and blood cancers.

Leave a Reply

Your email address will not be published. Required fields are marked *